Fractyl Health
- Biotech or pharma, therapeutic R&D
- Medical device or technology
*seeking partnerships for both platforms: clinical-stage, and pre-clinical*
Fractyl Health (Nasdaq: GUTS) is a clinical-stage metabolic therapeutics company pioneering potentially curative treatments for obesity and T2D.
Its lead product, Revita, is an endoscopic procedure designed to remodel the duodenal lining, aiming to sustain weight loss after discontinuation of GLP-1 therapies. The REMAIN-1 pivotal study (only study needed for approval) will complete enrollment this summer, with a midpoint data analysis anticipated in Q3 2025.
Fractyl is also advancing Rejuva, a nutrient-responsive “Smart” GLP-1 intrapancreatic (local) gene therapy, with plans to initiate the Clinical Trial Application (CTA) process in T2D by the end of Q2 2025 .
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}